Company: INKT
Filing Date: 2025-12-10
Form Type: S-3/A
Source: 0001193125-25-314252
Chunk: 16

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-12-10
Form: S-3/A
Chunk 16
---
 securities consisting of debentures, notes or other evidences of indebtedness; |

| • |     | units consisting of a combination of the foregoing securities; or |

| • |     | any combination of these securities. |

We may issue debt securities that are exchangeable for or convertible into common stock or any of the other securities that may be sold under this prospectus. When particular securities are offered, a supplement to this prospectus will be filed with the SEC, which will describe the terms of the offering and sale of the offered securities. If the information contained in the prospectus supplement differs from the following description, you should rely on the information in the prospectus supplement. Whenever references are made in this prospectus to information that will be included in a prospectus supplement, to the extent permitted by applicable law, rules or regulations, we may instead include such information or add, update or change the information contained in this prospectus by means of a post-effective amendment to the registration statement of which this prospectus is a part, through filings we make with the SEC that are incorporated by reference in this prospectus or by any other method as may be permitted under applicable law, rules or regulations. 12

DESCRIPTION OF OUR COMMON STOCK

The following description of our common stock and certain provisions of our amended and restated certificate of incorporation, or the Amended
and Restated Certificate of Incorporation, and amended and restated by-laws, or the Amended and Restated Bylaws are summaries and are qualified by reference to the Amended and Restated Certificate of
Incorporation and the Amended and Restated Bylaws, copies of which are on file with the SEC as exhibits to our Annual Report on Form 10-K for the year ended December 31, 2024. Please refer to “Where
You Can Find More Information” below for directions on obtaining these documents.

General

Our authorized capital stock consists of 150,000,000 shares of common stock, par value $0.00001 per share. As of September 30, 2025, we
had 4,600,585 shares of common stock outstanding.

Holders of our common stock are entitled to one vote for each share held on all
matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Holders of
common stock are entitled to receive